Fosun Yali Feng (Dalian) Biopharmaceutical Co., Ltd. is a Sino-foreign joint venture established through the integration of resources between Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and Yali Feng, a former vaccine enterprise under Italy’s Pharmathen Group. The company is positioned as a platform for research, development, manufacturing, and commercialization of human vaccines, focusing on routine immunization and booster immunization vaccines urgently needed for public health. Its core business spans the entire value chain of bacterial and viral vaccines. Its product pipeline includes a recombinant zoster vaccine (produced in CHO cells) currently in Phase III clinical trials; an adsorbed acellular diphtheria-tetanus-pertussis combination vaccine (DTaP) and a tetravalent meningococcal polysaccharide vaccine (serogroups A, C, Y, and W135), both at the stage of regulatory submission for market authorization. Its technological approaches encompass traditional inactivated/attenuated processes, recombinant protein technology, and novel adjuvant technologies. Leveraging its large-scale vaccine manufacturing base in Dalian, the company operates freeze-dried powder injection and liquid vaccine production lines compliant with both WHO prequalification requirements and China’s Good Manufacturing Practice (GMP) standards. It features a Grade B cleanroom facility, fully automated filling lines, and an ultra-low-temperature storage system maintained at -70°C, with an annual production capacity reaching tens of millions of doses. The company has obtained ISO 9001 Quality Management System certification and holds a “Drug Manufacturing License” (category code: vaccines) issued by the Liaoning Provincial Drug Administration, as well as “Drug Registration Certificates” or clinical trial approvals for multiple vaccine products. The company strictly adheres to the Chinese Pharmacopoeia (2020 Edition) and the Vaccine Administration Law, implementing quality management across the entire product lifecycle. Its products are distributed nationwide via Fosun Pharmaceutical’s mature distribution network, covering disease control and prevention centers (CDCs) and vaccination clinics in over 30 provinces and municipalities, thereby supporting both the National Immunization Program and adult immunization needs. The company engages in multidimensional collaborations—including joint vaccine R&D, technology transfer, contract manufacturing, regional supply, and digital vaccine management coordination—with government public health programs, CDCs, healthcare institutions, and industry partners across the vaccine value chain.